MAPT and early-onset autosomal dominant Alzheimer disease: In another study, MIPD was used to create D‐peptides with high affinity for the microtubule‐binding protein Tau, preventing self‐aggregation in the treatment of tauopathies.[80] The hexapeptides PHF6 (VQIINK) and PHF6* (VQIVYK) were found to promote Tau aggregation in tauopathies such as Alzheimer's disease, and their enantiomers have been used as a target for MIPD.[80, 83] Notably, two peptide candidates, MMD3 and MMD3rev, demonstrated cell‐penetrating properties, with the ability to cross the cell membrane of neurons.[83]